September 04, 2025

The Role of High-Quality Imaging for Posterior Chamber Phakic IOL Evaluation

Utilizing ANTERION®’s technology for confident planning and monitoring

The Ophthalmologist

September 02, 2025

Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could...

The ASCO Post

September 02, 2025

Cancer-Induced Nerve Injury Identified as Driver of PD-1 Resistance Across Tumor Types

Researchers have uncovered that cancer cells degrade protective nerve coverings, causing cancer-induced nerve injury that can lead to chronic inflammation and resistance to anti–PD-1 immunotherapy, ac...

The ASCO Post

September 02, 2025

Introducing the Ahmed ClearPath® ST: Evolving Design for Evolving Needs in Glaucoma Surgery

The Ahmed ClearPath® ST (ACP ST) represents the latest advancement in glaucoma drainage device design, offering surgeons a smaller-lumen, non-valved implant engineered to address evolving surgical challenges and techniques in the management of refractory glaucoma.

The Ophthalmologist

September 01, 2025

A Lens for Every Lifestyle

Understanding each patient’s visual needs, activities, and ocular health is vital to identifying the most appropriate IOL for that individual. 

Ophthalmology Management

August 22, 2025

Age Threshold for Survival Benefit of Adding Oxaliplatin to Adjuvant Chemotherapy in Stage II and III Colorectal Cancer

In a Korean retrospective study reported in JAMA Network Open, Bong et al found that the addition of oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy was associated with a survival benefit ...

The ASCO Post

August 22, 2025

Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

In a phase II study (ENGOT-OV60/GOG-3052/RAMP 201) reported in the Journal of Clinical Oncology, Banerjee et al evaluated the efficacy and safety of the RAF/MEK clamp avutometinib in combination with ...

The ASCO Post

August 22, 2025

Updated CHEST Guidelines Emphasize Minimally Invasive Surgery for Early-Stage NSCLC

Updated clinical guidelines for the management of patients with early-stage non–small cell lung cancer (NSCLC) from the American College of Chest Physicians (CHEST) recommend use of more minimally inv...

The ASCO Post

August 15, 2025

Nivolumab Added to Chemoradiotherapy Reduced Recurrence Risk in High-Risk Head and Neck Cancer

Adding the PD-1 inhibitor nivolumab to standard chemoradiotherapy after surgery significantly reduced recurrence rates for patients with locally advanced head and neck squamous cell carcinoma who are ...

The ASCO Post